her2阳性乳腺癌的基础标志物表达与预后和曲妥珠单抗耐药的关系

IF 42.1 1区医学 Q1 ONCOLOGY

Journal of Clinical Oncology Pub Date : 2014-05-20 DOI:10.1200/JCO.2014.32.15_SUPPL.608

A. Chung, M. Choi, S. Bose, Xiao Zhang, Marian M Varda, X. Cui, A. Giuliano

{"title":"her2阳性乳腺癌的基础标志物表达与预后和曲妥珠单抗耐药的关系","authors":"A. Chung, M. Choi, S. Bose, Xiao Zhang, Marian M Varda, X. Cui, A. Giuliano","doi":"10.1200/JCO.2014.32.15_SUPPL.608","DOIUrl":null,"url":null,"abstract":"608 Background: Herceptin resistance is a significant challenge in the treatment of Her2-positive (Her2+) breast cancer. A subset of Her2+ breast cancers are known to express basal genes (basal Her2). We investigated the effect of basal gene expression on cell viability and Herceptin response in Her2+ breast cancer cell lines and on prognosis in patients with Her2+ breast cancer who received Herceptin. Methods: We selected 4 cell lines to represent basal Her2 (HCC1569, HCC1954) and non-basal Her2 (BT474, SKBR3) breast cancer based on their basal gene signature in microarray analysis, and treated each with vehicle, Herceptin (H), Paclitaxel (P), and H + P. Cell viability was assessed by MTT assays. Her2 pathway suppression was compared between groups using immunoblotting with anti-Her2, p-AKT, p-ERK antibodies. Expression of CK5/6, CK14, and EGFR was evaluated after immunohistochemical staining in paraffin-embedded tissue of 88 patients with Stage 1-3 Her2+ breast cancer treated with chemotherapy and Herce...","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"32 1","pages":"608-608"},"PeriodicalIF":42.1000,"publicationDate":"2014-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association of basal marker expression with outcome and trastuzumab resistance in HER2-positive breast cancer.\",\"authors\":\"A. Chung, M. Choi, S. Bose, Xiao Zhang, Marian M Varda, X. Cui, A. Giuliano\",\"doi\":\"10.1200/JCO.2014.32.15_SUPPL.608\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"608 Background: Herceptin resistance is a significant challenge in the treatment of Her2-positive (Her2+) breast cancer. A subset of Her2+ breast cancers are known to express basal genes (basal Her2). We investigated the effect of basal gene expression on cell viability and Herceptin response in Her2+ breast cancer cell lines and on prognosis in patients with Her2+ breast cancer who received Herceptin. Methods: We selected 4 cell lines to represent basal Her2 (HCC1569, HCC1954) and non-basal Her2 (BT474, SKBR3) breast cancer based on their basal gene signature in microarray analysis, and treated each with vehicle, Herceptin (H), Paclitaxel (P), and H + P. Cell viability was assessed by MTT assays. Her2 pathway suppression was compared between groups using immunoblotting with anti-Her2, p-AKT, p-ERK antibodies. Expression of CK5/6, CK14, and EGFR was evaluated after immunohistochemical staining in paraffin-embedded tissue of 88 patients with Stage 1-3 Her2+ breast cancer treated with chemotherapy and Herce...\",\"PeriodicalId\":15384,\"journal\":{\"name\":\"Journal of Clinical Oncology\",\"volume\":\"32 1\",\"pages\":\"608-608\"},\"PeriodicalIF\":42.1000,\"publicationDate\":\"2014-05-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1200/JCO.2014.32.15_SUPPL.608\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/JCO.2014.32.15_SUPPL.608","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

608背景:赫赛汀耐药是Her2阳性(Her2+)乳腺癌治疗中的一个重大挑战。已知Her2阳性乳腺癌的一个亚群表达基础基因(基底Her2)。我们研究了基础基因表达对Her2+乳腺癌细胞系细胞活力和赫赛汀反应的影响，以及对接受赫赛汀治疗的Her2+乳腺癌患者预后的影响。方法:通过微阵列分析基础基因标记，选择4个细胞系作为基底型Her2 (HCC1569、HCC1954)和非基底型Her2 (BT474、SKBR3)乳腺癌的代表，分别用载体、赫赛汀(H)、紫杉醇(P)和H + P处理。采用抗Her2、p-AKT、p-ERK抗体免疫印迹法比较各组间Her2通路抑制情况。88例1-3期Her2+乳腺癌患者经化疗和Her2+治疗后，石蜡包埋组织经免疫组化染色，检测CK5/6、CK14和EGFR的表达。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Association of basal marker expression with outcome and trastuzumab resistance in HER2-positive breast cancer.

608 Background: Herceptin resistance is a significant challenge in the treatment of Her2-positive (Her2+) breast cancer. A subset of Her2+ breast cancers are known to express basal genes (basal Her2). We investigated the effect of basal gene expression on cell viability and Herceptin response in Her2+ breast cancer cell lines and on prognosis in patients with Her2+ breast cancer who received Herceptin. Methods: We selected 4 cell lines to represent basal Her2 (HCC1569, HCC1954) and non-basal Her2 (BT474, SKBR3) breast cancer based on their basal gene signature in microarray analysis, and treated each with vehicle, Herceptin (H), Paclitaxel (P), and H + P. Cell viability was assessed by MTT assays. Her2 pathway suppression was compared between groups using immunoblotting with anti-Her2, p-AKT, p-ERK antibodies. Expression of CK5/6, CK14, and EGFR was evaluated after immunohistochemical staining in paraffin-embedded tissue of 88 patients with Stage 1-3 Her2+ breast cancer treated with chemotherapy and Herce...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Clinical Oncology 医学-肿瘤学

CiteScore

41.20

自引率

2.20%

发文量

8215

审稿时长

2 months

期刊介绍： The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer.